What is PSA Doubling Time?
PSA Doubling Time (PSADT) is the time it takes for the serum PSA level to double. It is a kinetic measure that reflects the growth rate of prostate cancer and is one of the most important prognostic indicators following initial treatment (radical prostatectomy or radiation therapy).
A shorter doubling time indicates faster tumor growth and more aggressive disease, while a longer doubling time suggests indolent, slow-growing cancer. PSADT is particularly valuable in the setting of biochemical recurrence (BCR), where PSA rises after treatment without radiographic evidence of disease.
PSADT & PSA Velocity Formulas
Where ln is the natural logarithm, ln(2) ≈ 0.693, PSA1 is the initial PSA, PSA2 is the follow-up PSA, and Time is the interval between measurements.
PSA Velocity (PSAV) measures the absolute rate of PSA change per year:
Interpretation & Clinical Significance
| PSADT | Aggressiveness | Clinical Implication |
|---|---|---|
| < 3 months | Very aggressive | High risk of metastasis and cancer-specific mortality; urgent treatment change |
| 3 – 12 months | Aggressive | Consider salvage therapy or systemic treatment; imaging recommended |
| 12 – 24 months | Moderate | Active monitoring; treatment may be deferred with close surveillance |
| > 24 months | Slow / Indolent | Observation often appropriate; low risk of cancer-specific mortality |
PSA Velocity thresholds:
| Context | PSAV Threshold | Significance |
|---|---|---|
| Pre-diagnosis screening | > 0.75 ng/mL/year | Increased risk of prostate cancer |
| Post-prostatectomy | > 0.4 ng/mL/year | Suggests aggressive recurrence |
| Active surveillance | > 0.75 ng/mL/year | May trigger reclassification; consider intervention |
PSA Kinetics Diagram
PSA Monitoring After Treatment
After radical prostatectomy, PSA should become undetectable (< 0.1 ng/mL). A rising PSA after reaching nadir is defined as biochemical recurrence (BCR). After radiation therapy, BCR is defined by the Phoenix criteria: a rise of ≥ 2 ng/mL above the post-treatment nadir.
- Post-prostatectomy: PSA checked every 3–6 months for the first 5 years, then annually. BCR threshold: PSA ≥ 0.2 ng/mL (confirmed on repeat test)
- Post-radiation: PSA checked every 6 months. BCR: nadir + 2 ng/mL (Phoenix definition)
- Active surveillance: PSA every 3–6 months; PSADT helps determine when to intervene
Treatment Decision Framework
PSADT is a key factor in deciding between observation, salvage local therapy, and systemic therapy after BCR:
| PSADT | Time to BCR | Gleason | Suggested Approach |
|---|---|---|---|
| > 12 months | > 2 years | ≤ 7 | Observation or salvage radiation |
| 6 – 12 months | Any | Any | Salvage radiation + short-term ADT |
| 3 – 6 months | < 2 years | ≥ 8 | Salvage radiation + long-term ADT; consider systemic imaging |
| < 3 months | Any | Any | Systemic therapy (ADT ± chemotherapy); likely distant metastases |
Worked Example
A man has an initial PSA of 2.0 ng/mL and a follow-up PSA of 4.5 ng/mL, measured 12 months apart:
A PSADT of 10.25 months falls in the aggressive range (3–12 months), indicating rapidly progressing disease. The PSA velocity of 2.50 ng/mL/year is also significantly elevated. This patient should be considered for salvage therapy and advanced imaging (PSMA PET scan).
Frequently Asked Questions
How many PSA values are needed for accurate PSADT?
While two values are the minimum (as used in this calculator), three or more values over time provide a more reliable estimate. Multi-point PSADT calculations use linear regression on the log-transformed PSA values, which reduces the impact of PSA fluctuations.
Can PSADT be calculated if PSA decreases?
If the follow-up PSA is lower than the initial PSA, the PSADT calculation yields a negative number, indicating the PSA is declining rather than doubling. This is generally a favorable sign (response to treatment) and the concept of "doubling time" does not apply in that context.
What is the difference between PSADT and PSA velocity?
PSADT measures relative growth (time to double), reflecting exponential kinetics. PSA velocity measures absolute change per year. PSADT is more useful for prognostication in BCR because it accounts for the baseline PSA level, while PSAV can be misleading when baseline PSA is very high or very low.
Does PSADT predict overall survival?
Yes. Multiple large studies (Freedland, Pound, D'Amico) have shown that PSADT < 3 months after BCR is associated with significantly increased cancer-specific mortality and shorter overall survival. It is one of the strongest independent predictors of lethal prostate cancer.